A large new study by researchers from Intermountain Health has found that when clinicians take an “active” approach to statin selection, it more than doubles the rate of appropriate statin use in patients at risk for cardiovascular events. This approach, they found, also leads to lower LDL cholesterol in these patients and lower rates of major adverse cardiac events.
The team presented their results last week at the American College of Cardiology’s 2023 Scientific Session in New Orleans.
“When it comes to identifying who is likely to have a cardiac event, physicians are often playing catch up. They’re often looking at only one or another risk marker in an annual physical rather than making a formal multifactor risk assessment or are only uncovering the patient’s true risk after a heart or stroke,” said Jeffrey L. Anderson, cardiologist at Intermountain Health and principal investigator of the study.
“In this study, we’ve shown that taking a more active approach to help us find more patients who can benefit from a statin and hopefully prevent a heart attack, stroke, or cardiovascular death before it can happen.”
Statins can improve the prognosis and quality of the lives of patients who have or could develop heart disease. However, it’s not clear what is the best way to identify those who can benefit from a statin.
In this study, Intermountain researchers enrolled 3,770 patients 50 and older with no history of atherosclerotic cardiovascular disease or statin use in Intermountain’s Coronary Calcium (CorCal) study, which is studying the effectiveness of proactive lipid-lowering treatment approaches.
Of those, 601 agreed to be studied. They were given statin recommendations based on one of two risk assessment tools. One group was evaluated for coronary risk by the Pooled Cohort Equation, which estimates the risk of atherosclerotic cardiac disease within 10 years based on factors including age, gender, blood pressure, cholesterol, diabetes, and smoker status.
The other group was evaluated by coronary artery calcium scoring, which measures the presence and amount of coronary calcium based on a CT scan.
Each approach takes different factors into account, but both are considered “active statin selection methods”—as they are proactive approaches.
Patients who declined to enroll in CorCal were considered to be in the passive approach control group, i.e., receive usual care by their personal physicians. The groups were well matched on common risk factors.
The Intermountain team found that 41.7% of patients in the “active” group were appropriate to be recommended a statin. That translated into 25.3% of patients in the “active” group actually taking one, compared to 9.8% of the passive group during 2.8 years follow-up.
The “active” recommendation group also had more lipid panels, lower LDL-C and a trend to lower rates of major adverse cardiac events.
“This kind of active approach leads to more patients being checked more frequently for risk factors for coronary heart disease, and they were treated with statins more often, with the objective to lower their risk of a cardiovascular event such as a heart attack or stroke,” said Anderson.
“If we’re not actively assessing the risk of atherosclerotic cardiac disease with the aim of statin selection, we as physicians are much less likely to get statins to patients who could benefit from them. We also need to look for ways to further improve the results of our active approaches,” he added.
The Intermountain investigators are now involved in a 5,000+ patient trial to formally assess the impact of these active approach strategies on major adverse cardiovascular events—CorCal Outcomes.
